TNF and melanoma: Hence, we eagerly await the results from the first Phase Ib, open-label trial [128] that is evaluating the administration of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in combination with the anti-TNFα drug infliximab or certolizumab in patients with advanced melanoma.